Switch to:
Also traded in: Germany, Italy, Mexico, Spain, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.17
BAYRY's Cash to Debt is ranked lower than
83% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. BAYRY: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
BAYRY' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: 0.32 Max: No Debt
Current: 0.17
Equity to Asset 0.30
BAYRY's Equity to Asset is ranked lower than
88% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BAYRY: 0.30 )
Ranked among companies with meaningful Equity to Asset only.
BAYRY' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.35 Max: 0.46
Current: 0.3
0.21
0.46
Interest Coverage 12.33
BAYRY's Interest Coverage is ranked lower than
73% of the 474 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.03 vs. BAYRY: 12.33 )
Ranked among companies with meaningful Interest Coverage only.
BAYRY' s Interest Coverage Range Over the Past 10 Years
Min: 2.3  Med: 2.93 Max: 3.14
Current: 12.33
2.3
3.14
F-Score: 4
Z-Score: 1.94
M-Score: -2.60
WACC vs ROIC
8.68%
8.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.62
BAYRY's Operating margin (%) is ranked higher than
52% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.51 vs. BAYRY: 9.62 )
Ranked among companies with meaningful Operating margin (%) only.
BAYRY' s Operating margin (%) Range Over the Past 10 Years
Min: 7.78  Med: 9.96 Max: 11.36
Current: 9.62
7.78
11.36
Net-margin (%) 7.84
BAYRY's Net-margin (%) is ranked higher than
56% of the 684 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.44 vs. BAYRY: 7.84 )
Ranked among companies with meaningful Net-margin (%) only.
BAYRY' s Net-margin (%) Range Over the Past 10 Years
Min: 3.71  Med: 6.26 Max: 14.55
Current: 7.84
3.71
14.55
ROE (%) 17.22
BAYRY's ROE (%) is ranked higher than
77% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.23 vs. BAYRY: 17.22 )
Ranked among companies with meaningful ROE (%) only.
BAYRY' s ROE (%) Range Over the Past 10 Years
Min: 6.9  Med: 13.68 Max: 31.94
Current: 17.22
6.9
31.94
ROA (%) 5.14
BAYRY's ROA (%) is ranked higher than
57% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. BAYRY: 5.14 )
Ranked among companies with meaningful ROA (%) only.
BAYRY' s ROA (%) Range Over the Past 10 Years
Min: 2.54  Med: 4.46 Max: 8.78
Current: 5.14
2.54
8.78
ROC (Joel Greenblatt) (%) 25.29
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.81 vs. BAYRY: 25.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BAYRY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.91  Med: 24.40 Max: 28.5
Current: 25.29
17.91
28.5
Revenue Growth (3Y)(%) 5.00
BAYRY's Revenue Growth (3Y)(%) is ranked lower than
52% of the 581 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. BAYRY: 5.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BAYRY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.6  Med: 1.70 Max: 14
Current: 5
-10.6
14
EBITDA Growth (3Y)(%) 2.50
BAYRY's EBITDA Growth (3Y)(%) is ranked lower than
57% of the 528 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. BAYRY: 2.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BAYRY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.9  Med: 1.30 Max: 18.3
Current: 2.5
-9.9
18.3
EPS Growth (3Y)(%) 11.50
BAYRY's EPS Growth (3Y)(%) is ranked higher than
58% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. BAYRY: 11.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BAYRY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.1  Med: 7.35 Max: 41.2
Current: 11.5
-19.1
41.2
» BAYRY's 10-Y Financials

Financials (Next Earnings Date: 2016-02-25)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

BAYRY Guru Trades in Q1 2015

Ken Fisher 2,509,075 sh (+0.63%)
» More
Q2 2015

BAYRY Guru Trades in Q2 2015

Ken Fisher 4,610,296 sh (+83.74%)
» More
Q3 2015

BAYRY Guru Trades in Q3 2015

Ken Fisher 4,712,759 sh (+2.22%)
» More
Q4 2015

BAYRY Guru Trades in Q4 2015

Ken Fisher 4,709,574 sh (-0.07%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Bayer AG

Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Largest trades in second quarter include also Infosys and Alibaba
Ken Fisher (Trades, Portfolio) is the chief executive officer and chief investment officer of Fisher Investments, which offers an array of educational resources to its 27,000-plus private clients —including quarterly reports, in-person seminars and regular phone communication. Fisher Investments extends these educational resources to the public through a series of investing guides, online videos and daily commentary at MarketMinder.com. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 22.22
BAYRY's P/E(ttm) is ranked higher than
63% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.86 vs. BAYRY: 22.22 )
Ranked among companies with meaningful P/E(ttm) only.
BAYRY' s P/E(ttm) Range Over the Past 10 Years
Min: 8.67  Med: 22.36 Max: 36.88
Current: 22.22
8.67
36.88
Forward P/E 11.86
BAYRY's Forward P/E is ranked higher than
76% of the 419 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.50 vs. BAYRY: 11.86 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 21.91
BAYRY's PE(NRI) is ranked higher than
65% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.45 vs. BAYRY: 21.91 )
Ranked among companies with meaningful PE(NRI) only.
BAYRY' s PE(NRI) Range Over the Past 10 Years
Min: 14.08  Med: 23.62 Max: 37.24
Current: 21.91
14.08
37.24
P/B 3.64
BAYRY's P/B is ranked lower than
69% of the 928 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.54 vs. BAYRY: 3.64 )
Ranked among companies with meaningful P/B only.
BAYRY' s P/B Range Over the Past 10 Years
Min: 1.54  Med: 2.44 Max: 5.56
Current: 3.64
1.54
5.56
P/S 1.70
BAYRY's P/S is ranked higher than
64% of the 929 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.60 vs. BAYRY: 1.70 )
Ranked among companies with meaningful P/S only.
BAYRY' s P/S Range Over the Past 10 Years
Min: 0.77  Med: 1.31 Max: 2.75
Current: 1.7
0.77
2.75
PFCF 17.42
BAYRY's PFCF is ranked higher than
77% of the 485 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.85 vs. BAYRY: 17.42 )
Ranked among companies with meaningful PFCF only.
BAYRY' s PFCF Range Over the Past 10 Years
Min: 7.28  Med: 17.02 Max: 187
Current: 17.42
7.28
187
POCF 11.25
BAYRY's POCF is ranked higher than
81% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.68 vs. BAYRY: 11.25 )
Ranked among companies with meaningful POCF only.
BAYRY' s POCF Range Over the Past 10 Years
Min: 5.51  Med: 9.31 Max: 19.35
Current: 11.25
5.51
19.35
EV-to-EBIT 19.42
BAYRY's EV-to-EBIT is ranked higher than
50% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.42 vs. BAYRY: 19.42 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.2  Med: 17.20 Max: 31.7
Current: 19.42
7.2
31.7
EV-to-EBITDA 11.59
BAYRY's EV-to-EBITDA is ranked higher than
70% of the 852 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.91 vs. BAYRY: 11.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAYRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.4  Med: 9.90 Max: 18.4
Current: 11.59
4.4
18.4
PEG 5.20
BAYRY's PEG is ranked lower than
74% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. BAYRY: 5.20 )
Ranked among companies with meaningful PEG only.
BAYRY' s PEG Range Over the Past 10 Years
Min: 0.6  Med: 2.03 Max: 50.61
Current: 5.2
0.6
50.61
Shiller P/E 29.21
BAYRY's Shiller P/E is ranked higher than
70% of the 166 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.90 vs. BAYRY: 29.21 )
Ranked among companies with meaningful Shiller P/E only.
BAYRY' s Shiller P/E Range Over the Past 10 Years
Min: 20.1  Med: 32.99 Max: 44.57
Current: 29.21
20.1
44.57
Current Ratio 1.29
BAYRY's Current Ratio is ranked lower than
78% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. BAYRY: 1.29 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.53 Max: 2.13
Current: 1.29
1
2.13
Quick Ratio 0.84
BAYRY's Quick Ratio is ranked lower than
81% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. BAYRY: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.01 Max: 1.44
Current: 0.84
0.64
1.44
Days Inventory 144.40
BAYRY's Days Inventory is ranked lower than
63% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.42 vs. BAYRY: 144.40 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s Days Inventory Range Over the Past 10 Years
Min: 126.63  Med: 138.65 Max: 154.01
Current: 144.4
126.63
154.01
Days Sales Outstanding 77.73
BAYRY's Days Sales Outstanding is ranked lower than
52% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.67 vs. BAYRY: 77.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.71  Med: 69.96 Max: 78.61
Current: 77.73
65.71
78.61
Days Payable 87.01
BAYRY's Days Payable is ranked higher than
60% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. BAYRY: 87.01 )
Ranked among companies with meaningful Days Payable only.
BAYRY' s Days Payable Range Over the Past 10 Years
Min: 53.72  Med: 70.30 Max: 96.59
Current: 87.01
53.72
96.59

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.29
BAYRY's Dividend Yield is ranked higher than
70% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.43 vs. BAYRY: 2.29 )
Ranked among companies with meaningful Dividend Yield only.
BAYRY' s Dividend Yield Range Over the Past 10 Years
Min: 1.44  Med: 2.28 Max: 3.93
Current: 2.29
1.44
3.93
Dividend Payout 0.50
BAYRY's Dividend Payout is ranked lower than
70% of the 418 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. BAYRY: 0.50 )
Ranked among companies with meaningful Dividend Payout only.
BAYRY' s Dividend Payout Range Over the Past 10 Years
Min: 0.98  Med: 1.83 Max: 2.75
Current: 0.5
0.98
2.75
Dividend Growth (3y) 11.90
BAYRY's Dividend Growth (3y) is ranked higher than
62% of the 279 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. BAYRY: 11.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BAYRY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 1.80 Max: 34.9
Current: 11.9
0
34.9
Forward Dividend Yield 2.29
BAYRY's Forward Dividend Yield is ranked higher than
70% of the 614 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. BAYRY: 2.29 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.56
BAYRY's Yield on cost (5-Year) is ranked higher than
75% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.79 vs. BAYRY: 3.56 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAYRY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.23  Med: 3.52 Max: 6.07
Current: 3.56
2.23
6.07

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.42
BAYRY's Price/Projected FCF is ranked higher than
77% of the 523 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. BAYRY: 1.42 )
Ranked among companies with meaningful Price/Projected FCF only.
BAYRY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.77  Med: 1.61 Max: 2.25
Current: 1.42
0.77
2.25
Price/DCF (Earnings Based) 1.45
BAYRY's Price/DCF (Earnings Based) is ranked higher than
55% of the 124 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.55 vs. BAYRY: 1.45 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.32
BAYRY's Price/Median PS Value is ranked lower than
61% of the 899 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. BAYRY: 1.32 )
Ranked among companies with meaningful Price/Median PS Value only.
BAYRY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 0.92 Max: 3.5
Current: 1.32
0.24
3.5
Earnings Yield (Greenblatt) (%) 5.18
BAYRY's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 720 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BAYRY: 5.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAYRY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.2  Med: 5.80 Max: 13.9
Current: 5.18
3.2
13.9
Forward Rate of Return (Yacktman) (%) 14.50
BAYRY's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 318 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.62 vs. BAYRY: 14.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAYRY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.8  Med: 14.60 Max: 31.7
Current: 14.5
4.8
31.7

More Statistics

Revenue(Mil) $51016
EPS $ 4.84
Beta1.17
Short Percentage of Float0.01%
52-Week Range $107.00 - 156.77
Shares Outstanding(Mil)826.95

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 50,917 53,037 54,914 55,960
EPS($) 7.34 8.11 8.81 8.77
EPS without NRI($) 7.34 8.11 8.81 8.77

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BAYA.Germany, BAY.Italy, BAYN N.Mexico, BAY.Spain, BAYN.Switzerland,
Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third- largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing extensive customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
Bayer AG Wins Approval On Existing Antibiotic For Plague Treatment May 12 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
DuPont Eyeing Acquisition To Leverage Its Market Spread Apr 24 2015 
Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 

More From Other Websites
Bayer rejects EPA request to pull insecticide from U.S. market Feb 05 2016
Merck beats 4Q profit forecast, misses Street view on sales Feb 03 2016
Merck beats 4Q profit forecast, misses Street view on sales Feb 03 2016
Jadelle Access Program -- Bayer halves the price of its contraceptive implant Jadelle® for women in... Jan 08 2016
New edition of research, the Bayer scientific magazine, published -- Research for more quality of... Jan 07 2016
How Did FEZ’s Pharmaceutical Industry Perform? Jan 06 2016
Bayer AG downgraded by JP Morgan Jan 05 2016
ASCO GU 2016 to Feature Latest Xofigo Research from Bayer Jan 05 2016
Bayer closes on divestiture of Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for... Jan 05 2016
Panasonic Healthcare Holdings Completes Acquisition of Leading Diabetes Care Business from Bayer AG Jan 05 2016
[$$] Materials IPO Makes Strides Despite Headwinds Dec 29 2015
Bayer Rose 2.1% as It Increased Investments in Cancer Drugs Dec 23 2015
Moving Average Analysis of FEZ’s Pharmaceutical Industry Dec 23 2015
A major gene-editing company just got $335 million to get its technology into people Dec 21 2015
Bayer forms gene editing partnership with CRISPR Therapeutics Dec 21 2015
Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures... Dec 21 2015
[$$] Bayer in Venture With Gene-Editing Startup Dec 21 2015
Aspirin maker Bayer seeks to flex muscles in OTC sector Dec 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK